Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)

Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)

Abstract only

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2023-04, Vol.100 (17_supplement_2)
Hauptverfasser: Cerqueira, Joao, Berthele, Achim, Cree, Bruce, Filippi, Massimo, Pardo, Gabriel, Pearson, Owen, Traboulsee, Anthony, Ziemssen, Tjalf, Vollmer, Timothy, Bernasconi, Corrado, Mandel, Corey, Kulyk, Inessa, Chognot, Cathy, Schneble, Hans-Martin, Prajapati, Kalpesh, Havrdova, Eva
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 17_supplement_2
container_start_page
container_title Neurology
container_volume 100
creator Cerqueira, Joao
Berthele, Achim
Cree, Bruce
Filippi, Massimo
Pardo, Gabriel
Pearson, Owen
Traboulsee, Anthony
Ziemssen, Tjalf
Vollmer, Timothy
Bernasconi, Corrado
Mandel, Corey
Kulyk, Inessa
Chognot, Cathy
Schneble, Hans-Martin
Prajapati, Kalpesh
Havrdova, Eva
description Abstract only
doi_str_mv 10.1212/WNL.0000000000202195
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1212_WNL_0000000000202195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1212_WNL_0000000000202195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c965-8e8d92e131e1b3fdebb5c766a064bb194f9da3b0a2bf46e173586b5c691b5e9f3</originalsourceid><addsrcrecordid>eNpdkE1Lw0AQhhdRsFb_gYc96mHrfiSbrLdS2ipEU9pA9RR200ldSdKymxzirzdS8eBcBmYeXl4ehG4ZnTDO-MP2NZnQv-GUMxWeoRELuSRS8LdzNBrOMRFxFF-iK-8_KR2ekRqhNjk0e5KBq3HmQLc1NC3e2vYDL6zzLUlsAzgtHFT2q6u1wbbBK93aAfMnbq5d1eP1y-YRK_IO2uF0NV9P8aYze3fojnja6Kr31uO7TSCHnvz-Gl2UuvJw87vHKFvMs9kTSdLl82yakELJkMQQ7xQHJhgwI8odGBMWkZSaysAYpoJS7bQwVHNTBhJYJMJYDohUzISgSjFGwSm2cAfvHZT50dlauz5nNP8Rlw_i8v_ixDel5l-d</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)</title><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Cerqueira, Joao ; Berthele, Achim ; Cree, Bruce ; Filippi, Massimo ; Pardo, Gabriel ; Pearson, Owen ; Traboulsee, Anthony ; Ziemssen, Tjalf ; Vollmer, Timothy ; Bernasconi, Corrado ; Mandel, Corey ; Kulyk, Inessa ; Chognot, Cathy ; Schneble, Hans-Martin ; Prajapati, Kalpesh ; Havrdova, Eva</creator><creatorcontrib>Cerqueira, Joao ; Berthele, Achim ; Cree, Bruce ; Filippi, Massimo ; Pardo, Gabriel ; Pearson, Owen ; Traboulsee, Anthony ; Ziemssen, Tjalf ; Vollmer, Timothy ; Bernasconi, Corrado ; Mandel, Corey ; Kulyk, Inessa ; Chognot, Cathy ; Schneble, Hans-Martin ; Prajapati, Kalpesh ; Havrdova, Eva</creatorcontrib><description>Abstract only</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000202195</identifier><language>eng</language><ispartof>Neurology, 2023-04, Vol.100 (17_supplement_2)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c965-8e8d92e131e1b3fdebb5c766a064bb194f9da3b0a2bf46e173586b5c691b5e9f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Cerqueira, Joao</creatorcontrib><creatorcontrib>Berthele, Achim</creatorcontrib><creatorcontrib>Cree, Bruce</creatorcontrib><creatorcontrib>Filippi, Massimo</creatorcontrib><creatorcontrib>Pardo, Gabriel</creatorcontrib><creatorcontrib>Pearson, Owen</creatorcontrib><creatorcontrib>Traboulsee, Anthony</creatorcontrib><creatorcontrib>Ziemssen, Tjalf</creatorcontrib><creatorcontrib>Vollmer, Timothy</creatorcontrib><creatorcontrib>Bernasconi, Corrado</creatorcontrib><creatorcontrib>Mandel, Corey</creatorcontrib><creatorcontrib>Kulyk, Inessa</creatorcontrib><creatorcontrib>Chognot, Cathy</creatorcontrib><creatorcontrib>Schneble, Hans-Martin</creatorcontrib><creatorcontrib>Prajapati, Kalpesh</creatorcontrib><creatorcontrib>Havrdova, Eva</creatorcontrib><title>Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)</title><title>Neurology</title><description>Abstract only</description><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdkE1Lw0AQhhdRsFb_gYc96mHrfiSbrLdS2ipEU9pA9RR200ldSdKymxzirzdS8eBcBmYeXl4ehG4ZnTDO-MP2NZnQv-GUMxWeoRELuSRS8LdzNBrOMRFxFF-iK-8_KR2ekRqhNjk0e5KBq3HmQLc1NC3e2vYDL6zzLUlsAzgtHFT2q6u1wbbBK93aAfMnbq5d1eP1y-YRK_IO2uF0NV9P8aYze3fojnja6Kr31uO7TSCHnvz-Gl2UuvJw87vHKFvMs9kTSdLl82yakELJkMQQ7xQHJhgwI8odGBMWkZSaysAYpoJS7bQwVHNTBhJYJMJYDohUzISgSjFGwSm2cAfvHZT50dlauz5nNP8Rlw_i8v_ixDel5l-d</recordid><startdate>20230425</startdate><enddate>20230425</enddate><creator>Cerqueira, Joao</creator><creator>Berthele, Achim</creator><creator>Cree, Bruce</creator><creator>Filippi, Massimo</creator><creator>Pardo, Gabriel</creator><creator>Pearson, Owen</creator><creator>Traboulsee, Anthony</creator><creator>Ziemssen, Tjalf</creator><creator>Vollmer, Timothy</creator><creator>Bernasconi, Corrado</creator><creator>Mandel, Corey</creator><creator>Kulyk, Inessa</creator><creator>Chognot, Cathy</creator><creator>Schneble, Hans-Martin</creator><creator>Prajapati, Kalpesh</creator><creator>Havrdova, Eva</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230425</creationdate><title>Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)</title><author>Cerqueira, Joao ; Berthele, Achim ; Cree, Bruce ; Filippi, Massimo ; Pardo, Gabriel ; Pearson, Owen ; Traboulsee, Anthony ; Ziemssen, Tjalf ; Vollmer, Timothy ; Bernasconi, Corrado ; Mandel, Corey ; Kulyk, Inessa ; Chognot, Cathy ; Schneble, Hans-Martin ; Prajapati, Kalpesh ; Havrdova, Eva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c965-8e8d92e131e1b3fdebb5c766a064bb194f9da3b0a2bf46e173586b5c691b5e9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cerqueira, Joao</creatorcontrib><creatorcontrib>Berthele, Achim</creatorcontrib><creatorcontrib>Cree, Bruce</creatorcontrib><creatorcontrib>Filippi, Massimo</creatorcontrib><creatorcontrib>Pardo, Gabriel</creatorcontrib><creatorcontrib>Pearson, Owen</creatorcontrib><creatorcontrib>Traboulsee, Anthony</creatorcontrib><creatorcontrib>Ziemssen, Tjalf</creatorcontrib><creatorcontrib>Vollmer, Timothy</creatorcontrib><creatorcontrib>Bernasconi, Corrado</creatorcontrib><creatorcontrib>Mandel, Corey</creatorcontrib><creatorcontrib>Kulyk, Inessa</creatorcontrib><creatorcontrib>Chognot, Cathy</creatorcontrib><creatorcontrib>Schneble, Hans-Martin</creatorcontrib><creatorcontrib>Prajapati, Kalpesh</creatorcontrib><creatorcontrib>Havrdova, Eva</creatorcontrib><collection>CrossRef</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cerqueira, Joao</au><au>Berthele, Achim</au><au>Cree, Bruce</au><au>Filippi, Massimo</au><au>Pardo, Gabriel</au><au>Pearson, Owen</au><au>Traboulsee, Anthony</au><au>Ziemssen, Tjalf</au><au>Vollmer, Timothy</au><au>Bernasconi, Corrado</au><au>Mandel, Corey</au><au>Kulyk, Inessa</au><au>Chognot, Cathy</au><au>Schneble, Hans-Martin</au><au>Prajapati, Kalpesh</au><au>Havrdova, Eva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)</atitle><jtitle>Neurology</jtitle><date>2023-04-25</date><risdate>2023</risdate><volume>100</volume><issue>17_supplement_2</issue><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>Abstract only</abstract><doi>10.1212/WNL.0000000000202195</doi></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2023-04, Vol.100 (17_supplement_2)
issn 0028-3878
1526-632X
language eng
recordid cdi_crossref_primary_10_1212_WNL_0000000000202195
source Alma/SFX Local Collection; Journals@Ovid Complete
title Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A03%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Treatment%20With%20First-Line%20Ocrelizumab%20in%20Patients%20With%20Early%20RMS:%209-Year%20OPERA%20Subgroup%20Analysis%20(S46.002)&rft.jtitle=Neurology&rft.au=Cerqueira,%20Joao&rft.date=2023-04-25&rft.volume=100&rft.issue=17_supplement_2&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000202195&rft_dat=%3Ccrossref%3E10_1212_WNL_0000000000202195%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true